AC
ALNY icon

Allstate Corporation’s Alnylam Pharmaceuticals ALNY Stock Holding History

Allstate Corporation’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.46M Buy
8,185
+1,850
+29% +$558K 0.02% 393
2026
Q1 		$2.1M Sell
6,335
-3,494
-36% -$1.19M 0.02% 499
2025
Q4 		$3.91M Buy
9,829
+5,258
+115% +$2.33M 0.05% 228
2025
Q3 		$2.08M Buy
+4,571
New +$1.86M 0.05% 218
2025
Q2 		– Sell
-4,701
Closed -$1.27M – 194
2025
Q1 		$1.27M Buy
4,701
+903
+24% +$232K 0.04% 285
2024
Q4 		$894K Buy
+3,798
New +$999K 0.03% 341
2023
Q1 		– Sell
-5,228
Closed -$1.24M – 221
2022
Q4 		$1.24M Buy
5,228
+78
+2% +$16.6K 0.04% 302
2022
Q3 		$1.03M Buy
5,150
+358
+7% +$68.3K 0.03% 329
2022
Q2 		$699K Sell
4,792
-3,285
-41% -$466K 0.02% 424
2022
Q1 		$1.32M Sell
8,077
-2,782
-26% -$424K 0.04% 341
2021
Q4 		$1.84M Buy
10,859
+5,490
+102% +$1.02M 0.04% 414
2021
Q3 		$1.01M Sell
5,369
-445
-8% -$83.5K 0.04% 282
2021
Q2 		$986K Sell
5,814
-375
-6% -$54.9K 0.03% 308
2021
Q1 		$874K Buy
6,189
+973
+19% +$146K 0.03% 355
2020
Q4 		$678K Sell
5,216
-286
-5% -$38.2K 0.02% 381
2020
Q3 		$801K Sell
5,502
-158
-3% -$22.5K 0.03% 287
2020
Q2 		$838K Sell
5,660
-1,068
-16% -$144K 0.03% 298
2020
Q1 		$732K Sell
6,728
-8,296
-55% -$958K 0.03% 277
2019
Q4 		$1.73M Hold
15,024
– – 0.03% 332
2019
Q3 		$1.21M Buy
15,024
+11,290
+302% +$893K 0.02% 367
2019
Q2 		$271K Sell
3,734
-3,106
-45% -$238K ﹤0.01% 461
2019
Q1 		$639K Buy
6,840
+33
+0.5% +$2.76K 0.02% 325
2018
Q4 		$496K Buy
+6,807
New +$524K 0.02% 327

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Allstate Corporation's ALNY Position: Q2 2026 in Review

Allstate Corporation increased its Alnylam Pharmaceuticals (ALNY) stake by 29% in Q2 2026, buying an estimated $558K and bringing the position to 8,185 shares worth $2.46M. The position accounts for 0.02% of the portfolio, ranked #393.

Allstate Corporation first reported a position in ALNY in Q4 2018 and has held it in 23 quarters since. The position peaked at $3.91M in Q4 2025. 791 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

  • Allstate Corporation held 8,185 shares of Alnylam Pharmaceuticals worth $2.46M as of Q2 2026.
  • Allstate Corporation bought 1,850 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $558K.
  • Alnylam Pharmaceuticals made up 0.02% of Allstate Corporation's portfolio in Q2 2026, its #393 holding.
  • Allstate Corporation first reported a position in Alnylam Pharmaceuticals in Q4 2018 and has held it in 23 quarters since.
  • Allstate Corporation's Alnylam Pharmaceuticals position peaked at $3.91M in Q4 2025.
  • 791 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.